Complete depletion of specific B-cell subsets within 2 weeks of rituximab infusion is associated with clinical response in ...

A collaborative study published in Immunity from the Batista Lab and Liu Lab at the Ragon Institute, together with the Schief Lab at Scripps Research Institute, has uncovered a previously unrecognized ...

B cells are white blood cells that form a core part of the body's adaptive immune system, enabling it to recognize specific infections, remember them, and mount a targeted response by producing ...

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...

Researchers have created one of the most detailed maps to date of how white blood cells called B cells develop and behave ...

Please provide your email address to receive an email when new articles are posted on . Learning from 2 decades of off-label rituximab use in systemic lupus erythematosus may point the way toward ...

A 92-year-old man with a history of diffuse large B-cell lymphoma treated with chemoradiotherapy, and later with radiotherapy for an isolated cutaneous relapse with complete response, presented with a ...

Immunotherapies such as CAR T-cell therapy are used primarily to treat cancer. In the future, these patient-specific ...